Free Trial

Achieve Life Sciences Q1 2023 Earnings Report

Achieve Life Sciences logo
$2.78 -0.12 (-4.14%)
As of 03/28/2025 04:00 PM Eastern

Achieve Life Sciences EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Achieve Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Achieve Life Sciences Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Achieve Life Sciences Earnings Headlines

Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
ACHV: 2Q:25 NDA Submission
Lake Street Keeps Their Buy Rating on Achieve Life Sciences (ACHV)
See More Achieve Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Achieve Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achieve Life Sciences and other key companies, straight to your email.

About Achieve Life Sciences

Achieve Life Sciences (NASDAQ:ACHV), a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

View Achieve Life Sciences Profile

More Earnings Resources from MarketBeat